FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087332538> ?p ?o ?g. }

• W2087332538 endingPage "2566" @default.
• W2087332538 startingPage "2562" @default.
• W2087332538 abstract "Interferon alpha is used for the adjuvant treatment of malignant melanoma at different dosages (high-, intermediate-, low-dose therapy). Only a minority of patients might benefit from this therapy, and markers to identify such patients are missing. A recent study suggested that melanoma patients developing autoantibodies or clinical manifestations of autoimmunity during adjuvant high-dose interferon alpha treatment had a significant survival benefit. We retrospectively reviewed 134 melanoma patients from our institution treated with adjuvant low-dose interferon alpha therapy and correlated the development of autoimmune diseases with prognosis. Interferon (IFN) therapy was routinely monitored by history, physical examination and laboratory tests before, after the first month and then after every 3 months of therapy. During a median follow up of 46.0 months (8.5-79.0 months) 28 patients (20.9%) suffered from recurrences and melanoma related deaths occurred in 16 patients (11.9%). In 20 patients (14.9%) autoimmune thyroiditis (AIT) was diagnosed during IFN therapy, one of these 20 patients developed rheumatoid arthritis later while continuing IFN therapy. Other autoimmune diseases were not observed. In 2 patients (one with AIT and one with arthritis) the autoimmune disease led to discontinuation of IFN therapy, in the other patients AIT remained subclinical or responded well to treatment while IFN therapy was continued. Kaplan-Meier analyses revealed a significant better recurrence free survival and a trend for a better overall survival for patients with AIT. Thus, autoimmunity triggered by low-dose IFN therapy appears to indicate an improved prognosis and should encourage continuation of IFN therapy." @default.
• W2087332538 created "2016-06-24" @default.
• W2087332538 creator A5015081105 @default.
• W2087332538 creator A5016449107 @default.
• W2087332538 creator A5018435692 @default.
• W2087332538 creator A5044736874 @default.
• W2087332538 creator A5084108111 @default.
• W2087332538 creator A5089096323 @default.
• W2087332538 date "2007-08-06" @default.
• W2087332538 modified "2023-10-15" @default.
• W2087332538 title "Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha" @default.
• W2087332538 cites W1805116264 @default.
• W2087332538 cites W1823669223 @default.
• W2087332538 cites W1909858390 @default.
• W2087332538 cites W1911828475 @default.
• W2087332538 cites W1984273763 @default.
• W2087332538 cites W1986032822 @default.
• W2087332538 cites W1993355758 @default.
• W2087332538 cites W1996669689 @default.
• W2087332538 cites W2056390097 @default.
• W2087332538 cites W2062716630 @default.
• W2087332538 cites W2074895307 @default.
• W2087332538 cites W2088015974 @default.
• W2087332538 cites W2109336050 @default.
• W2087332538 cites W2117039280 @default.
• W2087332538 cites W2131365547 @default.
• W2087332538 cites W2134880837 @default.
• W2087332538 cites W2143923888 @default.
• W2087332538 cites W2161671887 @default.
• W2087332538 cites W2169720423 @default.
• W2087332538 cites W2465751741 @default.
• W2087332538 cites W4241141024 @default.
• W2087332538 cites W4256189622 @default.
• W2087332538 cites W4322702510 @default.
• W2087332538 cites W4375940934 @default.
• W2087332538 doi "https://doi.org/10.1002/ijc.22951" @default.
• W2087332538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17680564" @default.
• W2087332538 hasPublicationYear "2007" @default.
• W2087332538 type Work @default.
• W2087332538 sameAs 2087332538 @default.
• W2087332538 citedByCount "32" @default.
• W2087332538 countsByYear W20873325382013 @default.
• W2087332538 countsByYear W20873325382014 @default.
• W2087332538 countsByYear W20873325382015 @default.
• W2087332538 countsByYear W20873325382016 @default.
• W2087332538 countsByYear W20873325382017 @default.
• W2087332538 countsByYear W20873325382022 @default.
• W2087332538 crossrefType "journal-article" @default.
• W2087332538 hasAuthorship W2087332538A5015081105 @default.
• W2087332538 hasAuthorship W2087332538A5016449107 @default.
• W2087332538 hasAuthorship W2087332538A5018435692 @default.
• W2087332538 hasAuthorship W2087332538A5044736874 @default.
• W2087332538 hasAuthorship W2087332538A5084108111 @default.
• W2087332538 hasAuthorship W2087332538A5089096323 @default.
• W2087332538 hasConcept C113280763 @default.
• W2087332538 hasConcept C126322002 @default.
• W2087332538 hasConcept C143998085 @default.
• W2087332538 hasConcept C203014093 @default.
• W2087332538 hasConcept C2776178377 @default.
• W2087332538 hasConcept C2776694085 @default.
• W2087332538 hasConcept C2777575956 @default.
• W2087332538 hasConcept C2777658100 @default.
• W2087332538 hasConcept C2777863537 @default.
• W2087332538 hasConcept C2777982462 @default.
• W2087332538 hasConcept C2778715236 @default.
• W2087332538 hasConcept C2779075594 @default.
• W2087332538 hasConcept C2779134260 @default.
• W2087332538 hasConcept C2780130043 @default.
• W2087332538 hasConcept C2781228144 @default.
• W2087332538 hasConcept C2909179924 @default.
• W2087332538 hasConcept C502942594 @default.
• W2087332538 hasConcept C71924100 @default.
• W2087332538 hasConcept C90924648 @default.
• W2087332538 hasConceptScore W2087332538C113280763 @default.
• W2087332538 hasConceptScore W2087332538C126322002 @default.
• W2087332538 hasConceptScore W2087332538C143998085 @default.
• W2087332538 hasConceptScore W2087332538C203014093 @default.
• W2087332538 hasConceptScore W2087332538C2776178377 @default.
• W2087332538 hasConceptScore W2087332538C2776694085 @default.
• W2087332538 hasConceptScore W2087332538C2777575956 @default.
• W2087332538 hasConceptScore W2087332538C2777658100 @default.
• W2087332538 hasConceptScore W2087332538C2777863537 @default.
• W2087332538 hasConceptScore W2087332538C2777982462 @default.
• W2087332538 hasConceptScore W2087332538C2778715236 @default.
• W2087332538 hasConceptScore W2087332538C2779075594 @default.
• W2087332538 hasConceptScore W2087332538C2779134260 @default.
• W2087332538 hasConceptScore W2087332538C2780130043 @default.
• W2087332538 hasConceptScore W2087332538C2781228144 @default.
• W2087332538 hasConceptScore W2087332538C2909179924 @default.
• W2087332538 hasConceptScore W2087332538C502942594 @default.
• W2087332538 hasConceptScore W2087332538C71924100 @default.
• W2087332538 hasConceptScore W2087332538C90924648 @default.
• W2087332538 hasIssue "11" @default.
• W2087332538 hasLocation W20873325381 @default.
• W2087332538 hasLocation W20873325382 @default.
• W2087332538 hasOpenAccess W2087332538 @default.
• W2087332538 hasPrimaryLocation W20873325381 @default.
• W2087332538 hasRelatedWork W1489705104 @default.

• next